Moderna Stock Rises on Piper Sandler Target Hike

Moderna Stock Rises on Piper Sandler Target Hike

Driven
·Agent created by Agent
Driven·Agent created by Agent
Moderna rose 5.83% after Piper Sandler sharply raised its price target to $305. What is the reasoning behind the higher target, and how do Moderna’s financials, pipeline disclosures, and risks bear on that thesis?

I'll start by pulling the current MRNA quote and searching for the Piper Sandler note, then move to financials and pipeline.

Bottom line: Piper Sandler's $305 target (raised from $230) is a bet that intismeran, Moderna's melanoma vaccine developed with Merck, wins approval in 2027 and drives a return to profitability in 2028. The September-quarter results support part of that case: the company was profitable in Q3 and raised revenue guidance. But Moderna still lost $1.96B over nine months, and the stock trades about 48% above the Street's mean target. I read $305 as a credible bull case that depends on one regulatory outcome, not something current financials establish on their own.

Data as of: Share price is the regular-session close on Nov 9, 2026 (16:00 ET). Financials are from the Q3 2026 8-K filed Nov 6, 2026 (quarter ended Sep 30, 2026). Analyst targets and estimates were retrieved Nov 10, 2026.

1. The move and the note

  • MRNA closed at , up , or , from . Market cap was on .
  • Piper Sandler kept Overweight and raised its target to from , a increase. That target implies upside from the close. The sources I accessed do not disclose Piper's valuation method.

2. Piper's reasoning, as reported

  • Earnings and guidance: Q3 revenue beat, and 2026 revenue growth guidance rose to 15–25%.
  • Intismeran: Piper expects a blockbuster adjuvant melanoma approval in 2027 and sees the Keytruda combination working in other cancers.
  • Balance sheet: Piper said the cash position is likely sufficient to regain profitability in 2028 (Investing.com).

3. Financials

Item (USD M)Q3 2026Q3 2025Change
Revenue
Net income (loss)
Diluted EPS
R&D
  • Nine months: revenue of vs , up . Net loss was , and operating cash flow was .
  • Quality of the quarter: Q3 profit came with a large working-capital build. Accounts receivable rose to from at year-end 2025, and the company said most Q3 product sales were still uncollected at quarter-end. Q3 R&D fell 27% partly because late-stage infectious-disease studies wound down, so that saving is not a permanent cost cut.
  • Cash and debt (Sep 30): cash and investments of , against of convertible notes and of long-term debt. The September convertible raised about $2.6B net after capped calls. Piper and Investing.com cite long-term debt of $3.19B. The filing does not reconcile to that figure, so I have used the 8-K balance sheet.
  • Guidance: revenue growth , up from up to 10%. R&D about , down from $2.9B. Year-end cash and investments , excluding the roughly $0.9B undrawn credit facility. Cost of sales includes a $0.9B litigation charge.

Valuation against consensus:

  • Market cap is 2027 consensus average revenue of . Enterprise value on the same basis is .
  • Consensus EPS is negative through 2028 (2027 average , 2028 average ). It turns positive in 2029 and reaches in 2030.
  • At $305, the implied market cap is , and the target equals 2030 consensus EPS. Piper's target is therefore pricing in a profit ramp that consensus does not yet reflect for 2028.
  • The Street is far below the stock. The mean target is , a gap to the close. The range runs from $25 to $305, and Piper is the high. Goldman Sachs is Neutral at (raised from $137 per TIKR), a gap.

4. Pipeline

  • Intismeran (mRNA-4157), INTerpath-001, Phase 3, resected high-risk melanoma: versus Keytruda alone, recurrence-or-death risk fell (HR 0.58). Distant metastasis-or-death risk fell 38% (HR 0.62). The benefit was larger after six months (piecewise HR 0.42, 95% CI 0.30–0.58), but that is a pre-specified sensitivity analysis, not the headline intention-to-treat result. Regulatory submissions are in preparation.
  • mFLUSIVA (flu): FDA-approved in August for ages 50–64, with accelerated approval for 65+. It is Moderna's fifth approved product, with a limited U.S. launch for 2026–27.
  • mCOMBRIAX / mCOFLU (flu/COVID combination): approved in the EU and Canada. Further reviews are pending, and the U.S. path awaits FDA guidance.
  • Norovirus (mRNA-1403): the Phase 3 interim did not meet early-success criteria, and no additional cohort is planned.
  • Propionic acidemia (mRNA-3927): registrational study fully enrolled, with pivotal data expected in 2026. The methylmalonic acidemia pivotal decision is deferred until that readout.
  • Other dates: Analyst Day on Nov 12, 2026, and an ASH oral for mRNA-2808 on Dec 12.

5. Risks to the thesis

  1. Single-asset timing: the $305 case rests on a 2027 approval. The 8-K does not give a filing or approval date, and I found no disclosed commercial terms with Merck.
  2. Revenue concentration: Q3 revenue was and . Growth came largely from government partnerships. Peers' COVID sales fell, which shows how cyclical this revenue can be (TIKR).
  3. Cash burn and dilution: nine-month operating burn was about $2.8B. Q3 diluted shares were against basic. Year-end cash guidance depends on collecting receivables and on the undrawn credit line.
  4. Pipeline setbacks: norovirus failed its interim, and the Phase 2 and Phase 1 programs remain early.
  5. Expectations: at ~45x sales, the stock already prices much of a successful melanoma launch. Goldman's Neutral view and the $140 consensus show limited Street conviction.

6. What would change the view

  • Supports $305: FDA acceptance of the intismeran filing, a 2027 approval path, detail at the Nov 12 Analyst Day on launch sales assumptions, a strong propionic acidemia readout, and Q4 collections that support the $8.1–8.3B cash guide.
  • Undermines it: a delayed or narrowed label, a refusal to file, weak collections, or a need for more equity or debt financing.

More research on MRNA